Navigation Links
Favrille Announces $21.1 Million Registered Direct Offering
Date:11/2/2007

SAN DIEGO, Nov. 2 /PRNewswire-FirstCall/ -- Favrille, Inc. (Nasdaq: FVRL) announced today that the Company has entered into definitive agreements with primarily institutional investors to sell up to 7,416,520 shares of its common stock and warrants to purchase up to 4,449,910 shares of its common stock for gross proceeds of approximately $21.1 million, before deducting placement agent fees and estimated offering expenses, in a "registered direct" offering. The investors have agreed to purchase the shares of common stock and warrants to purchase common stock (together, a "unit") at a negotiated purchase price of $2.845 per unit, each unit consisting of one share and a warrant to purchase 0.6 shares of common stock. The warrants will be exercisable at any time prior to the fifth anniversary of the closing of the transaction. The exercise price of the warrants will be $2.77 per share.

Lazard Capital Markets LLC served as sole placement agent for the offering.

The securities described above are being offered by the Company pursuant to a previously filed registration statement, which was declared effective by the Securities and Exchange Commission (the "SEC") on July 11, 2006. The transaction is expected to close on or about November 7, 2007, subject to customary closing conditions. The Company intends to use the net proceeds from this offering to fund its efforts to obtain FDA approval for its lead drug candidate FavId(R), to prepare for commercial launch of FavId and for other general corporate purposes.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state. Copies of the final prospectus supplement and accompanying base prospectus relating to this offering may be obtained at the SEC's website at '/>"/>

SOURCE Favrille, Inc.
Copyright©2007 PR Newswire.
All rights reserved

1

GOOD

Page: 1 2 3

Related biology technology :

1. Speaker announces business members of IT Task Force
2. Doyle announces technology tax credits for Berbee
3. Doyle announces new energy, global warming policies
4. Doyle announces $80M renewable energy strategy
5. GE announces first installation of Discovery VCT
6. UWM announces winners of RGI awards
7. Third Wave announces two senior management appointments
8. Mirus announces new method for making antibodies
9. Merge announces sofware updates, upcoming acquisition
10. Small Tree announces ethernet solution for Apple Xserv G5
11. TEKLYNX International announces new RFID software
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/17/2013)... , May 17, 2013  Cellular Biomedicine ... achieved 50% enrollment of the total projected enrollment ... the safety and preliminary efficacy of the medical ... for Knee Osteoarthritis (KOA). To date the trial ... The Phase I open label clinical ...
(Date:5/17/2013)... 2013 /PRNewswire-iReach/ -- Aridis is pleased to announce ... Switzerland -based Kenta Biotech to acquire ... (mAb) products, and technologies. This asset portfolio purchase ... of infections by common pathogens including drug resistant ... Pseudomonas aeruginosa , Acinetobacter baumannii and ...
(Date:5/17/2013)... (PRWEB) May 17, 2013 Men’s skin is ... La-roche Posay ) and has been known to react ... some men may be far from puberty, other acne causing ... pores, causing breakouts, and threatening skin with unsightly acne scars. ... from Men’s Health on how to reduce and ...
(Date:5/17/2013)... May 17, 2013 RURO Inc. ... version 4.1, a versatile refinement to the smart ... solution, improves its advanced methodical management for transgenic ... ezColony 4.1. The network-based platform provides user access ... research. While continuing to emphasize streamlined tasks, such ...
Breaking Biology Technology:Cellular Biomedicine Group Achieves 50% Enrollment Milestone in Phase I Clinical Trial for Knee Osteoarthritis 2Aridis Pharmaceuticals Announces Acquisition of Monoclonal Antibody Products and Technologies From Kenta Biotech 2Aridis Pharmaceuticals Announces Acquisition of Monoclonal Antibody Products and Technologies From Kenta Biotech 3Adult Acne Treatment, Probiotic Action Shares New Insight on Why Men’s Skin Scars from Acne and How to Prevent It 2RURO Introduces ezColony 4.1 – The Versatile Transgenic Animal Colony Management Software 2
... - PAS-Port(R) Proximal Anastomosis System Received 510(k) Clearance from ... Food and Drug Administration (FDA) -, - Development Progress Triggered $1M Milestone ... - Conference Call Today at 4:30 p.m. Eastern Time -, ... today reported financial results and corporate progress,for its fiscal 2009 first quarter ...
... Beckman,Coulter, Inc. (NYSE: BEC ), announced today ... Adventist Health to provide a broad range of ... million over,six years. Adventist Health is a not-for-profit, ... Oregon, and Washington., (Logo: http://www.newscom.com/cgi-bin/prnh/20031202/BECLOGO ), ...
... ... Clinical Business, SUNNYVALE, Calif., Oct. 28 Cepheid (Nasdaq:,CPHD) today ... of 24% over the third quarter of fiscal 2007. Net loss,was $6.5 ... a net loss of $4.7 million, or $(0.09) per share, in the ...
Cached Biology Technology:Cardica Announces Fiscal 2009 First Quarter Financial Results 2Cardica Announces Fiscal 2009 First Quarter Financial Results 3Cardica Announces Fiscal 2009 First Quarter Financial Results 4Cardica Announces Fiscal 2009 First Quarter Financial Results 5Cardica Announces Fiscal 2009 First Quarter Financial Results 6Beckman Coulter Signs Agreements with Adventist Health; Broad Product Offering Enhances Delivery of Quality Patient Care 2Cepheid Reports Third Quarter Revenue of $44.9 Million 2Cepheid Reports Third Quarter Revenue of $44.9 Million 3Cepheid Reports Third Quarter Revenue of $44.9 Million 4Cepheid Reports Third Quarter Revenue of $44.9 Million 5Cepheid Reports Third Quarter Revenue of $44.9 Million 6Cepheid Reports Third Quarter Revenue of $44.9 Million 7Cepheid Reports Third Quarter Revenue of $44.9 Million 8Cepheid Reports Third Quarter Revenue of $44.9 Million 9Cepheid Reports Third Quarter Revenue of $44.9 Million 10Cepheid Reports Third Quarter Revenue of $44.9 Million 11Cepheid Reports Third Quarter Revenue of $44.9 Million 12Cepheid Reports Third Quarter Revenue of $44.9 Million 13
(Date:5/17/2013)... Atlanta residents of all ages will celebrate the ... impact on our daily lives during the inaugural ... engineers and educators from local museums, corporations, K-12 ... than 40 different events for children and adults ... http://atlantasciencefestival.org . , The annual Atlanta ...
(Date:5/17/2013)... new Dartmouth College study finds human-caused climate change ... tropical lizards, contradicting a host of recent studies ... warming planet. , The findings, which appear in ... new hope for survival of a creature thought ... predictions that tropical cold-blooded animals, especially forest lizards, ...
(Date:5/16/2013)... (Maximizing Access to Research Careers) Program has announced ... (ENDO) 95th Annual Meeting in San Francisco, CA ... to promote the entry of students, postdoctorates and ... the basic science community and to encourage the ... Annual Meeting. , Awards are given to poster/platform ...
Breaking Biology News(10 mins):First Atlanta Science Festival set for 2014 2Climate change may have little impact on tropical lizards 2
... have long been puzzled by a condition called ... of the brain become elongated and misshapen. Typically, ... ("hardening of the arteries"), and not directly life-threatening. ... dolichoectasia are more likely to have aortic aneurysms, ...
... species (ROS), or 'oxygen radicals', have been identified as ... prevalence linked to inflammation-associated syndromes and a variety of ... San Diego Branch of the Ludwig Institute for Cancer ... repair and cell cycle control genes in yeast that ...
... time when everything was big has helped Queensland researchers ... humans, was responsible for wiping out Australian giant marsupials ... excavating 'trophy specimens' such as giant kangaroos and wombats, ... Queensland Museum performed the first systematic analysis of a ...
Cached Biology News:Mystery Blood Vessel Disorder Implicated In 'Mini' Strokes 2Yeast Network Prevents Damage By Oxygen Radicals 2Small species back-up giant marsupial climate change extinction claim 2Small species back-up giant marsupial climate change extinction claim 3
Human peripheral blood CD19+ B cells, For immunohistochemistry (IHC) Cell Chip with Human Peripheral Blood Monocytes, B Cells, NK Cells and Stem Cells...
Human peripheral blood basophils, For immunohistochemistry (IHC) Cell Chip with Human Peripheral Blood Granulocytes...
Umbilical cord blood CD4+ T cells, For immunohistochemistry (IHC) Cell Chip with Human Umbilical Cord Blood MNCs and T Cells...
... an anodized aluminum, solvent-resistant block specially designed ... efficient thermal transfer to samples within the ... HT96 Isothermal Block replaces Cat. No. 71031-3, ... for compatibility with robotic applications. The new ...
Biology Products: